[Clostridium-difficile-associated diarrhea]

Gastroenterol Hepatol. 2009 Jan;32(1):48-56. doi: 10.1016/j.gastrohep.2008.02.003. Epub 2008 Dec 31.
[Article in Spanish]

Abstract

Clostridium difficile is the most frequent cause of nosocomial diarrhea and is a significant cause of morbidity among hospitalized patients. The inflammation is produced as a result of a non-specific response to toxins. In the last few years, a hypervirulent strain, NAP1/BI/027, has been reported. Symptoms usually consist of abdominal pain and diarrhea. The diagnosis should be suspected in any patient who develops diarrhea during antibiotic therapy or 6-8 weeks after treatment. Diagnosis should be confirmed by the detection of CD toxin in stool and by colonoscopy in special situations. The treatment of choice is metronidazole or vancomycin. In some patients who do not respond to this therapy or who have complications, subtotal colectomy may be required. Relapse is frequent and must be distinguished from reinfection. Prevention and control in healthcare settings requires careful attention.

Publication types

  • Review

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Toxins / analysis
  • Biological Therapy
  • Clostridioides difficile / isolation & purification
  • Clostridioides difficile / physiology*
  • Colectomy
  • Colonoscopy
  • Combined Modality Therapy
  • Cross Infection / diagnosis
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Cross Infection / prevention & control
  • Cross Infection / therapy
  • DNA, Bacterial / analysis
  • Diarrhea / diagnosis
  • Diarrhea / epidemiology
  • Diarrhea / microbiology*
  • Diarrhea / prevention & control
  • Diarrhea / therapy
  • Enterocolitis, Pseudomembranous / diagnosis
  • Enterocolitis, Pseudomembranous / epidemiology
  • Enterocolitis, Pseudomembranous / microbiology*
  • Enterocolitis, Pseudomembranous / prevention & control
  • Enterocolitis, Pseudomembranous / therapy
  • Female
  • Humans
  • Immunocompromised Host
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant, Newborn
  • Male
  • Metronidazole / therapeutic use
  • Probiotics / therapeutic use
  • Recurrence
  • Risk Factors
  • Superinfection / epidemiology
  • Superinfection / microbiology
  • Superinfection / prevention & control
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Bacterial Toxins
  • DNA, Bacterial
  • Immunoglobulins, Intravenous
  • Metronidazole
  • Vancomycin